Walleye Capital LLC Enanta Pharmaceuticals Inc Transaction History

Walleye Capital LLC

  • $46.2 Billion
  • Q3 2024

A detailed history of Walleye Capital LLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Walleye Capital LLC holds 43,899 shares of ENTA stock, worth $444,696. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,899
Previous 22,349 96.42%
Holding current value
$444,696
Previous $289,000 57.44%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$10.05 - $16.54 $216,577 - $356,437
21,550 Added 96.42%
43,899 $455,000
Q2 2024

Aug 14, 2024
BUY
$11.43 - $17.02 $255,449 - $380,379
22,349 New
22,349 $289,000
Q4 2023

Feb 14, 2024
SELL
$8.18 - $10.78 $596,117 - $785,592
-72,875 Reduced 61.05%
46,489 $437,000
Q3 2023

Nov 14, 2023
BUY
$11.09 - $22.13 $1.02 Million - $2.05 Million
92,410 Added 342.84%
119,364 $1.33 Million
Q2 2023

Aug 14, 2023
BUY
$20.68 - $39.85 $557,408 - $1.07 Million
26,954 New
26,954 $576,000
Q2 2022

Aug 08, 2022
SELL
$38.13 - $76.93 $2.4 Million - $4.85 Million
-63,046 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$56.06 - $74.11 $1.9 Million - $2.51 Million
33,846 Added 115.91%
63,046 $4.49 Million
Q4 2021

Mar 03, 2022
BUY
$60.19 - $97.37 $1.76 Million - $2.84 Million
29,200 New
29,200 $2.18 Million
Q2 2020

Aug 14, 2020
SELL
$46.37 - $57.58 $250,490 - $311,047
-5,402 Closed
0 $0
Q1 2020

May 15, 2020
BUY
$40.22 - $62.0 $217,268 - $334,924
5,402 New
5,402 $278,000

Others Institutions Holding ENTA

# of Institutions
111
Shares Held
20.9M
Call Options Held
4.8K
Put Options Held
4.6K
View Full List

About ENANTA PHARMACEUTICALS INC

ENTA Quotes by TradingView
  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $210M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email